Characterization of recombinant hERG K(+) channel inhibition by the active metabolite of amiodarone desethyl-amiodarone
- PMID: 20493497
- DOI: 10.1016/j.jelectrocard.2010.04.007
Characterization of recombinant hERG K(+) channel inhibition by the active metabolite of amiodarone desethyl-amiodarone
Abstract
The aim of this study was to determine the effects of desethyl-amiodarone (DEA), the major metabolite of the class III antiarrhythmic drug amiodarone, on human ether-à-go-go-related gene (hERG) encoded potassium channel current.
Materials and methods: Whole-cell patch clamp recordings were made at 37 degrees C of ionic current (I(hERG)) carried by recombinant hERG channels expressed in HEK-293 cells.
Results: Desethyl-amiodarone inhibited I(hERG) with a half-maximal inhibitory concentration of approximately 158 nmol/L, compared with approximately 47 nmol/L for amiodarone. The inhibitory action of DEA on I(hERG) was contingent on channel gating, showing significant time and voltage dependence. Desethyl-amiodarone also produced an approximately -9 mV shift in the voltage dependence of activation of I(hERG); however, there was no significant preference for activated over inactivated channels.
Conclusions: Because hERG underlies native cardiac "I(Kr)" channels, hERG/I(Kr) inhibition by DEA as well as amiodarone may contribute to the overall effects of amiodarone administration on cardiac repolarization.
Copyright 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.Cardiol J. 2008;15(3):209-19. Cardiol J. 2008. PMID: 18651412 Review.
-
Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues.Br J Pharmacol. 2008 Oct;155(4):585-95. doi: 10.1038/bjp.2008.287. Epub 2008 Jul 7. Br J Pharmacol. 2008. PMID: 18604229 Free PMC article.
-
Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives.J Pharmacol Exp Ther. 2006 Dec;319(3):1413-23. doi: 10.1124/jpet.106.108993. Epub 2006 Sep 13. J Pharmacol Exp Ther. 2006. PMID: 16971508
-
Removal of human ether-à-go-go related gene (hERG) K+ channel affinity through rigidity: a case of clofilium analogues.J Med Chem. 2013 Dec 12;56(23):9427-40. doi: 10.1021/jm4010434. Epub 2013 Nov 25. J Med Chem. 2013. PMID: 24224763
-
The hERG potassium channel and hERG screening for drug-induced torsades de pointes.Pharmacol Ther. 2008 Aug;119(2):118-32. doi: 10.1016/j.pharmthera.2008.05.009. Epub 2008 Jun 18. Pharmacol Ther. 2008. PMID: 18616963 Review.
Cited by
-
Structural implications of hERG K+ channel block by a high-affinity minimally structured blocker.J Biol Chem. 2018 May 4;293(18):7040-7057. doi: 10.1074/jbc.RA117.000363. Epub 2018 Mar 15. J Biol Chem. 2018. PMID: 29545312 Free PMC article.
-
High potency inhibition of hERG potassium channels by the sodium-calcium exchange inhibitor KB-R7943.Br J Pharmacol. 2012 Apr;165(7):2260-73. doi: 10.1111/j.1476-5381.2011.01688.x. Br J Pharmacol. 2012. PMID: 21950687 Free PMC article.
-
Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking.Biochem Pharmacol. 2016 Aug 1;113:24-35. doi: 10.1016/j.bcp.2016.05.013. Epub 2016 May 30. Biochem Pharmacol. 2016. PMID: 27256139 Free PMC article.
-
Characterization of hERG K+ channel inhibition by the new class III antiarrhythmic drug cavutilide.Naunyn Schmiedebergs Arch Pharmacol. 2024 Jul;397(7):5093-5104. doi: 10.1007/s00210-023-02940-5. Epub 2024 Jan 15. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38224347
-
State-independent inhibition of the oncogenic Kv10.1 channel by desethylamiodarone, a comparison with amiodarone.Pflugers Arch. 2024 Mar;476(3):323-335. doi: 10.1007/s00424-023-02893-x. Epub 2023 Dec 8. Pflugers Arch. 2024. PMID: 38063872 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous